3-(alpha-phenylpropyl)-4-hydroxycoumarin

Liquamar

2H-1-benzopyran-2-one, 4-hydroxy-3-(1-phenylpropyl)-

An orally available, long-acting derivative of coumarin with anticoagulant activity. Upon administration, phenprocoumon inhibits the vitamin K epoxide reductase enzyme; inhibition of this enzyme prevents the formation of the reduced, active form of vitamin K (vitamin KH2), which is essential for the carboxylation of glutamate residues of vitamin K-dependent proteins. This prevents the activation of vitamin K-dependent coagulation factors II, VII, IX, and X and the anticoagulant proteins C and S, which abrogates both thrombin production and thrombus formation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66374" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66374" NCI Thesaurus)

http://purl.bioontology.org/ontology/PDQ/CDR0000750561

3-(alpha-phenylpropyl)-4-hydroxycoumarin

Liquamar

2H-1-benzopyran-2-one, 4-hydroxy-3-(1-phenylpropyl)-

435-97-2

C0918267

C0031444

2013-06-19

2013-07-10

An orally available, long-acting derivative of coumarin with anticoagulant activity. Upon administration, phenprocoumon inhibits the vitamin K epoxide reductase enzyme; inhibition of this enzyme prevents the formation of the reduced, active form of vitamin K (vitamin KH2), which is essential for the carboxylation of glutamate residues of vitamin K-dependent proteins. This prevents the activation of vitamin K-dependent coagulation factors II, VII, IX, and X and the anticoagulant proteins C and S, which abrogates both thrombin production and thrombus formation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66374" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66374" NCI Thesaurus)

TRD

C66374

CDR0000750561

Drug/agent

phenprocoumon

T109

T121